Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for Depression in Multiple Sclerosis
NCT00151294Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and emotional lability (PBA) comparing Escitalopram with Placebo (2 arms). Primary endpoints: Reduction in depressive symptom scores at 6 weeks and Adverse events at 6 weeks. Started Nov 2004; status: terminated.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)emotional lability (PBA)
Beyond the preview
Go deeper on NCT00151294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151294.